3 Minutes
Imagine your morning espresso doing more than jolt you awake—what if it nudged your metabolism in a way that trims body fat and lowers diabetes risk? That provocative possibility is the takeaway from a 2023 genetic study that tracked how caffeine circulating in the blood relates to body mass and disease vulnerability.
Researchers from the Karolinska Institute, the University of Bristol and Imperial College London turned to existing genetic databases, analyzing data from just under 10,000 people. Instead of asking how many cups participants drank, the team followed genetic variations near two key genes—CYP1A2 and AHR—that influence how quickly caffeine is broken down. Those differences can leave caffeine lingering in the bloodstream longer, even if the carriers tend to drink less coffee overall.
Using Mendelian randomization, a method that leverages genetic variation to probe cause-and-effect, the researchers found a clear pattern: genetically predicted higher plasma caffeine concentrations were linked to lower BMI and reduced whole-body fat mass, and to a lower likelihood of developing type 2 diabetes. About half of the apparent protective effect against diabetes seemed to flow through reductions in BMI.
Curious? So were the team. They drilled into other outcomes too and found no convincing connection between blood caffeine levels and major cardiovascular events—no stronger signal for atrial fibrillation, heart failure or stroke emerged from the data. That separates the diabetes-related association from broader cardiovascular claims that sometimes swirl around headlines about coffee and health.
How might caffeine pull this off? The favored explanations point to increased thermogenesis—more heat production—and elevated fat oxidation, meaning the body burns a bit more stored fat for energy. Small, short-term trials have shown modest weight and fat loss with caffeine, which jibes with the genetics-based result. But small and short are not the same as decisive.
There are caveats. Mendelian randomization is powerful, but not foolproof; unmeasured factors could be whispering in the background. As Benjamin Woolf, a genetic epidemiologist at the University of Bristol, put it: "Randomized controlled trials are warranted to assess whether non-caloric caffeine-containing beverages might play a role in reducing the risk of obesity and type 2 diabetes." In plain terms: the genetic hints are interesting, but only controlled trials can test whether giving people caffeine actually reduces weight and diabetes risk over time.
For now, the finding is a nudge—an invitation to study whether calorie-free caffeinated drinks could complement public-health strategies around obesity and metabolic disease. The next step is a trial that treats this genetic whisper like a hypothesis worth proving or disproving. Would you volunteer for a study that asks you to swap one beverage for another and see whether your metabolic fate shifts? The answer could change how we think about a very ordinary daily habit.
Source: sciencealert
Leave a Comment